The SAFE-HEaRt pilot study is designed to evaluate the cardiac safety of HER2 targeted therapy in 30 patients with HER2-positive breast cancer and mildly reduced LVEF.
Does HER2 targeted therapy with optimized cardiac therapy maintain cardiac safety in patients with HER2 positive breast cancer and mildly reduced LVEF (40-49%)?
The SAFE-HEaRt pilot study is designed to prospectively evaluate the cardiac safety of HER2 targeted therapies in breast cancer patients with mildly reduced LVEF receiving optimized cardiac therapy.
BACKGROUND: Human epidermal growth receptor 2 (HER2) targeted therapies have survival benefit in adjuvant and metastatic HER2 positive breast cancer but are associated with cardiac dysfunction. Current U.S. Food and Drug Administration recommendations limit the use of HER2 targeted agents to patients with normal left ventricular (LV) systolic function. METHODS: The objective of the SAFE-HEaRt study is to evaluate the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and mildly reduced left ventricular ejection fraction (LVEF) with optimized cardiac therapy. Thirty patients with histologically confirmed HER2 positive breast cancer (stage I-IV) and reduced LVEF (40% to 49%) who plan to receive HER2 targeted therapy for ≥3 months will be enrolled. Prior to initiation on study, optimization of heart function with beta-blockers and angiotensin converting enzyme inhibitors will be initiated. Patients will be followed by serial echocardiograms and cardiac visits during and 6 months after completion of HER2 targeted therapy. Myocardial strain and blood biomarkers, including cardiac troponin I and high-sensitivity cardiac troponin T, will be examined at baseline and during the study. DISCUSSION: 2017;22:518-525 IMPLICATIONS FOR PRACTICE: Human epidermal growth receptor 2 (HER2) targeted therapies have survival benefit in adjuvant and metastatic HER2 positive breast cancer but are associated with cardiac dysfunction. To our knowledge, SAFE-HEaRt is the first clinical trial that prospectively tests the hypothesis that HER2 targeted therapies may be safely administered in patients with mildly reduced cardiac function in the setting of ongoing cardiac treatment and monitoring. The results of this study will provide cardiac safety data and inform consideration of clinical practice changes in patients with HER2 positive breast cancer and reduced cardiac function, as well as provide information regarding cardiovascular monitoring and treatment in this population.
Lynce et al. (2017) studied HER2-positive breast cancer with reduced left ventricular function (n=30). HER2 targeted therapy with optimized cardiac therapy was evaluated on Cardiac safety. The SAFE-HEaRt pilot study is designed to evaluate the cardiac safety of HER2 targeted therapy in 30 patients with HER2-positive breast cancer and mildly reduced LVEF.